The Pipeline

Our two clinical-stage product candidates, Inupadenant (EOS-850) and EOS-448, each target a key mechanism that inhibits an effective antitumor immune response: the ATP adenosine pathway and a novel checkpoint TIGIT, respectively. We believe that both product candidates have the potential to further increase patient responses to standard cancer therapies, including immunotherapy. We are evaluating numerous biomarkers in our clinical programs to maximize this potential through choosing synergistic combination agents and identifying patients most likely to benefit from our product candidates. 

We are also using our deep understanding of the critical immune resistance pathways to identify new targets and generate additional differentiated programs for underexploited pathways validated by a strong scientific rationale.


Program Trial Design Indications Preclinical Phase 1 Phase 1b/2a Key upcoming milestones
Adenosine Pathway
Inupadenant (EOS-850)
Monotherapy Solid tumors
Initial expansion results 1H 2021
+ pembrolizumab PD-1-Resistant Melanoma
Initiated 3Q 2020
+ pembrolizumab Castrate-R Prostate Cancer
Initiated 3Q 2020
+ Pac-Carbo TNBC
Initiated 3Q 2020
Treg Targeting
Dose Finding, PK/PD Solid tumors
Presentation of initial results 1H 2021
Mono / + Combo Multiple Myeloma
Initiation mid-2021
Initiation mid-2021
Inupadenant +/- Chemo Solid Tumors
Initiation mid-2021
Preclinical pipeline
Adenosine Pathway Inhibitor
Candidate selection in 2021